Should I Buy PBH? PBH 2026 Analysis

Should You Buy Prestige Consumer Healthcare Inc (PBH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

66.330

1 Day change

1.19%

52 Week Range

90.040

Analysis Updated At

2026/01/30

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now. PBH is trading pre-market around 62.68, slipping below nearby support (S1 ~63.31) while momentum indicators are turning more bearish (MACD histogram negative and expanding). With no Intellectia buy signals, weakening recent quarter growth, and pattern-based probabilities pointing to further downside over the next week/month, the risk/reward is unfavorable for an impatient buyer today.

Technical Analysis

Trend/Momentum: Bearish-to-neutral. The MACD histogram (-0.286) is below zero and negatively expanding, signaling building downside momentum. RSI(6) ~41.8 is neutral but leaning weak (not oversold). Moving averages are converging, which often precedes a larger move; given MACD/price action, bias is currently down.

Key levels: Pivot 65.43 is the important reclaim level for bulls. Pre-market ~62.68 is below S1 63.31 and closer to S2 62.00; that places the stock in a fragile zone where small selling pressure can cascade. Resistance sits at 67.55 (R1) then 68.86 (R2).

Quant/pattern read: The provided candlestick-analog stats indicate a 60% chance of -1.84% next day, -13.31% next week, and -10.16% next month—consistent with a near-term bearish setup.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock today.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment from positioning: Open interest put/call of 0.23 is call-heavy (bullish positioning/skew), while volume put/call is 0.0 (today’s activity is minimal—only ~1 contract traded), so the "bullish" read is more about existing positioning than fresh conviction.

Volatility: Implied vol (30d) ~42.82 vs historical vol ~19.18 implies options are pricing elevated uncertainty. IV percentile ~75 suggests IV is high relative to its own history, which often coincides with event risk (earnings upcoming) or downside fear. Net: options are not confirming a clean bullish entry; they’re pricing uncertainty.

Technical Summary

Sell

Buy

Positive Catalysts

suggests more calls than puts outstanding.
on 2026-02-05 pre-market (Est EPS 1.
could re-rate the stock if results/guide beat.

Neutral/Negative Catalysts

with a negatively expanding MACD increases near-term downside odds.

Financial Performance

Latest quarter: 2026/Q2.

Revenue: 274.114M, down -3.41% YoY (top-line contraction).
Net Income: 42.211M, down -22.37% YoY (profitability weakening faster than sales).
EPS: 0.86, down -21.10% YoY.
Gross Margin: 53.41%, down -0.17% YoY (slight margin erosion). Overall: The quarter shows negative growth trends (sales and earnings down), which makes it harder to justify buying into a weakening tape without a strong technical/quant signal.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend (PBH-specific): On 2025-11-07, Canaccord lowered its price target on Prestige Consumer to $88 from $100 but maintained a Buy rating, citing results that were solid but benefited from timing items (supply timing / retailer order timing) that may shift between quarters.

Note on provided dataset: Several analyst items listed (Scotiabank/TD/Canaccord/Stifel/RBC on 2025-12-18) reference "Premium Brands" and CAD price targets, which do not appear to match PBH (Prestige Consumer Healthcare). Using only the clearly relevant PBH entry, the Street view is: rating remains positive (Buy) but price target was cut, implying reduced near-term conviction.

Wall Street pros vs cons (from the available PBH note):

Pros: Maintained Buy; acknowledged execution that exceeded expectations.
Cons: Benefit partly driven by timing, which can reverse in subsequent quarters—adds to earnings/quarterly volatility risk.

Influential trading (politicians/insiders/congress): No recent congress trades available; insiders are neutral with no significant recent trend.

PBH Should I Buy